Fluconazole vs. Flucytosine in the Treatment of Esophageal Candidiasis in AIDS Patients: A Double-Blind, Placebo-Controlled Study
Abstract
BACKGROUND AND STUDY AIMS: Contrasting opinions exist as to the pharmacological treatment of esophageal candidiasis in human immunodeficiency virus (HIV)-positive patients. The aim of this study has been to evaluate the role, therapeutic efficacy, and the cost-benefit ratio of two antifungal drugs, fluconazole and flucytosine, compared with a placebo, in the treatment of endoscopically-diagnosed esophageal candidiasis in patients with acquired immune deficiency syndrome (AIDS). PATIENTS AND METHODS: The study included 60 HIV-positive patients (38 males and 22 females, mean age 27 +/- 2) with a first episode of esophageal candidiasis diagnosed by endoscopy (grades I-II of Kodsi's endoscopic classification, and grades I-IIa of Barbaro's clinical classification). No other opportunistic infection of the esophagus was detected. In a double-blind procedure, patients were randomized into three groups of 20 patients each, receiving either fluconazole (3 mg/kg/daily per os), flucytosine (100 mg/kg/daily per os) or placebo. After two weeks of treatment, the patients previously assigned to receive the placebo were double-blindly randomized to receive fluconazole (eight patients) or flucytosine (nine patients). In order to evaluate the efficacy of pharmacological therapy, clinical examination was performed at weeks 2 and 5, and then every week up to the end of follow-up (three months); endoscopic examination was performed at weeks 2 and 5, and at the end of follow-up. RESULTS: At week 2, endoscopic cure (grade 0) was observed in 13 patients (65%) of the fluconazole group and in three patients (15%) in the flucytosine group (relative risk ratio: 0.23; 95% C.I.: 0.10-0.48; p < 0.05), and a partial endoscopic response (grade I) was observed in two patients (10%) in the placebo group. Complete clinical remission (grade 0) was observed in 16 patients (80%) in the fluconazole group and 12 patients (60%) in the flucytosine group (relative risk ratio: 0.75; 95% C.I.: 0.42-0.89; p = n.s.), while six patients (30%) in the placebo group presented partial clinical remission (grade I). At the end of follow-up, endoscopic cure was observed in 19 patients (70%) in the fluconazole group and in nine patients (33%) in the flucytosine group (relative risk ratio: 0.47; 95% C.I.: 0.19-0.65; p < 0.05). Complete clinical remission was observed in 21 patients (77.7%) in the fluconazole group and in 17 patients (63%) in the flucytosine group (relative risk ratio: 0.81; 95% C.I.: 0.53-0.92; p = n.s.). No noticeable side-effects were observed in the patients in either treatment group, without a statistically significant difference in comparison with the placebo. CONCLUSIONS: The results of this study have demonstrated that both fluconazole and flucytosine are safe and well tolerated in the treatment of esophageal candidiasis in AIDS patients. Fluconazole showed greater therapeutic efficacy than flucytosine, with a difference that was statistically significant in terms of the rate of endoscopic cure.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Fluconazole is superior to ketoconazole, itraconazole capsules, and flucytosine for treatment of esophageal candidiasis.
“Fluconazole is superior to ketoconazole, itraconazole capsules, and flucytosine for the treatment of esophageal candidiasis [278][279][280].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [280]
Cited by
Sorted by citations
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · see citing works
Practice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927 · see citing works
Vermes, A. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.2.171 · Cited by 803 · see citing works
Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334 · see citing works
Krause, D. S., Simjee, A. E., van Rensburg, C. E. J., Viljoen, J., Walsh, T. J., Goldstein, B. P., Wible, M., & Henkel, T. (2004) · Clinical Infectious Diseases · doi:10.1086/423378 · Cited by 241 · see citing works
Wet, N. T. E. D., Llanos‐Cuentas, A., Suleiman, J. M. A. H., Baraldi, E., Krantz, E., Negra, M. D., & Diekmann-Berndt, H. (2004) · Clinical Infectious Diseases · doi:10.1086/423377 · Cited by 203 · see citing works
Lortholary, O., Πετρίκκος, Γ., Akova, M., Arendrup, M. C., Arıkan-Akdağlı, S., Bassetti, M., Billé, J., Calandra, T., Castagnola, E., Cornely, O. A., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12042 · Cited by 108 · see citing works
Pienaar, E. D., Young, T., & Holmes, H. K. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003940.pub3 · Cited by 104 · see citing works
Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine
Patel, R. (1998) · Mayo Clinic Proceedings · doi:10.4065/73.12.1205 · Cited by 106 · see citing works
Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection
Vazquez, J. (2010) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s6660 · Cited by 81 · see citing works
Vázquez, J. A. (2000) · HIV Clinical Trials · doi:10.1310/t7a7-1e63-2ka0-jkwd · Cited by 74 · see citing works
Infections of the esophagus: an update on risk factors, diagnosis, and management
Hoversten, P., Kamboj, A. K., & Katzka, D. A. (2018) · Diseases of the Esophagus · doi:10.1093/dote/doy094 · Cited by 71 · see citing works
Options for the Management of Mucosal Candidiasis in Patients with AIDS and HIV Infection
Vázquez, J. A. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.1.76.30509 · Cited by 62 · see citing works
Bárbaro, G., Barbarini, G., & Lorenzo, G. D. (1996) · CHEST Journal · doi:10.1378/chest.110.6.1507 · Cited by 37 · see citing works
Self-citationOesophageal Candidiasis in Elderly Patients
Weerasuriya, N., & Snape, J. (2008) · Drugs & Aging · doi:10.2165/00002512-200825020-00004 · Cited by 34 · see citing works
Pienaar, E. D., Young, T., & Holmes, H. K. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003940.pub2 · Cited by 25 · see citing works
Wellmer, A., & Bernhardt, H. (1997) · Mycoses · doi:10.1111/j.1439-0507.1997.tb00251.x · Cited by 20 · see citing works
The therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome
Wilcox, C. M., & Mönkemüller, K. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.00159.x · Cited by 17 · see citing works
Podzamczer, D., Arribas, J. R., Mallolas, J., Peña, J. M., Pulido, F., Aguirrebengoa, K., Barros, C., Blázquez, R., Costa, J. R., Dronda, F., et al. (2001) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(01)72670-5 · Cited by 17 · see citing works
Zeng, B., Zeng, B., Hung, C., Chen, T., Wu, Y., Tu, Y., Lin, P., Su, K., Stubbs, B., Sun, C., et al. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1922078 · Cited by 12 · see citing works
Management of Oropharyngeal and Esophageal Candidiasis in Patients with Hiv Infection
Vazquez, J. A. (2010) · HIV Therapy · doi:10.2217/hiv.10.18 · Cited by 5 · see citing works
Mucocutaneous and Deeply Invasive Candidiasis
Shoham, S., Nucci, M., & Walsh, T. J. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3935-5.00088-4 · Cited by 4 · see citing works
Infective Esophagitis: a Review of Esophageal Diseases in HIV
Ali, A. A., Sanders, K., McCarthy, A. M., et al. (2023) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-023-00435-z · Cited by 2 · see citing works
Oropharyngeal and Esophageal Candidiasis in Immunocompromised Patients: Treatment Issues
Rabih (2016) · Cited by 1 · see citing works
Drew, R. H. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-12
Georgiev, V. S. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-296-8_20 · Cited by 1 · see citing works
- Authors
- Barbaro, G., Barbarini, G., & Di Lorenzo, G.
- Affiliations
- University of Pavia (IT)
- ORCID
- Barbarini, G.
- Venue
- Endoscopy
- Publisher
- Georg Thieme Verlag KG
- Published
- 1995-06
- Volume
- 27
- Issue
- 05
- Pages
- 377-383
- ISSN
- 0013-726X (ISSN-L)
- 1438-8812
- OpenAlex
- W1986784762
- Cited by
- 27
- References
- 0
- Citations by year
- 2023: 1 · 2021: 1 · 2018: 1 · 2016: 1 · 2012: 2
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endoscopy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV/AIDS oral health manifestations
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- esophageal candidiasis, AIDS, HIV infection, fluconazole, 5-fluorocytosine, antifungal therapy, treatment efficacy, benefit-cost ratio, opportunistic infections, endoscopic classification, clinical remission, drug comparison, antifungal resistance
- MeSH terms
- Acquired Immunodeficiency Syndrome, Adult, Antifungal Agents, Candidiasis, Double-Blind Method, Esophagitis, Esophagoscopy, Female, Flucytosine, Humans, Male, Fluconazole, AIDS-Related Opportunistic Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
